These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
216 related articles for article (PubMed ID: 17300945)
1. Lost in translation: treatment trials in the SOD1 mouse and in human ALS. Benatar M Neurobiol Dis; 2007 Apr; 26(1):1-13. PubMed ID: 17300945 [TBL] [Abstract][Full Text] [Related]
2. Therapeutic immunization with a glatiramer acetate derivative does not alter survival in G93A and G37R SOD1 mouse models of familial ALS. Haenggeli C; Julien JP; Mosley RL; Perez N; Dhar A; Gendelman HE; Rothstein JD Neurobiol Dis; 2007 Apr; 26(1):146-52. PubMed ID: 17276077 [TBL] [Abstract][Full Text] [Related]
3. Motor neuron dysfunction in a mouse model of ALS: gender-dependent effect of P2X7 antagonism. Cervetto C; Frattaroli D; Maura G; Marcoli M Toxicology; 2013 Sep; 311(1-2):69-77. PubMed ID: 23583883 [TBL] [Abstract][Full Text] [Related]
4. Vascular endothelial growth factor prolongs survival in a transgenic mouse model of ALS. Zheng C; Nennesmo I; Fadeel B; Henter JI Ann Neurol; 2004 Oct; 56(4):564-7. PubMed ID: 15389897 [TBL] [Abstract][Full Text] [Related]
5. Recombinant human erythropoietin suppresses symptom onset and progression of G93A-SOD1 mouse model of ALS by preventing motor neuron death and inflammation. Koh SH; Kim Y; Kim HY; Cho GW; Kim KS; Kim SH Eur J Neurosci; 2007 Apr; 25(7):1923-30. PubMed ID: 17439481 [TBL] [Abstract][Full Text] [Related]
6. Treatment with minocycline after disease onset alters astrocyte reactivity and increases microgliosis in SOD1 mutant mice. Keller AF; Gravel M; Kriz J Exp Neurol; 2011 Mar; 228(1):69-79. PubMed ID: 21168408 [TBL] [Abstract][Full Text] [Related]
7. Therapeutic effects of CuII(atsm) in the SOD1-G37R mouse model of amyotrophic lateral sclerosis. McAllum EJ; Lim NK; Hickey JL; Paterson BM; Donnelly PS; Li QX; Liddell JR; Barnham KJ; White AR; Crouch PJ Amyotroph Lateral Scler Frontotemporal Degener; 2013 Dec; 14(7-8):586-90. PubMed ID: 23952668 [TBL] [Abstract][Full Text] [Related]
8. Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS. Zhang W; Narayanan M; Friedlander RM Ann Neurol; 2003 Feb; 53(2):267-70. PubMed ID: 12557297 [TBL] [Abstract][Full Text] [Related]
9. Manganese porphyrin given at symptom onset markedly extends survival of ALS mice. Crow JP; Calingasan NY; Chen J; Hill JL; Beal MF Ann Neurol; 2005 Aug; 58(2):258-65. PubMed ID: 16049935 [TBL] [Abstract][Full Text] [Related]
10. A therapeutic role for cyclooxygenase-2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. Pompl PN; Ho L; Bianchi M; McManus T; Qin W; Pasinetti GM FASEB J; 2003 Apr; 17(6):725-7. PubMed ID: 12586733 [TBL] [Abstract][Full Text] [Related]
11. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Mackenzie IR; Bigio EH; Ince PG; Geser F; Neumann M; Cairns NJ; Kwong LK; Forman MS; Ravits J; Stewart H; Eisen A; McClusky L; Kretzschmar HA; Monoranu CM; Highley JR; Kirby J; Siddique T; Shaw PJ; Lee VM; Trojanowski JQ Ann Neurol; 2007 May; 61(5):427-34. PubMed ID: 17469116 [TBL] [Abstract][Full Text] [Related]
12. Human Cu/Zn superoxide dismutase (SOD1) overexpression in mice causes mitochondrial vacuolization, axonal degeneration, and premature motoneuron death and accelerates motoneuron disease in mice expressing a familial amyotrophic lateral sclerosis mutant SOD1. Jaarsma D; Haasdijk ED; Grashorn JA; Hawkins R; van Duijn W; Verspaget HW; London J; Holstege JC Neurobiol Dis; 2000 Dec; 7(6 Pt B):623-43. PubMed ID: 11114261 [TBL] [Abstract][Full Text] [Related]
13. Efficient three-drug cocktail for disease induced by mutant superoxide dismutase. Kriz J; Gowing G; Julien JP Ann Neurol; 2003 Apr; 53(4):429-36. PubMed ID: 12666110 [TBL] [Abstract][Full Text] [Related]